You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

4SCAR19

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)

Recruiting
  • B Cell Malignancies
  • Universal CD19-specific CAR gene-engineered T cells
  • Beijing, Beijing, China
  • +2 more
Aug 8, 2023

B-Cell Leukemia, B-Cell Lymphoma Trial in Guangzhou (4SCAR19/22 T cells, Interleukin-2)

Suspended
  • B-Cell Leukemia
  • B-Cell Lymphoma
  • Guangzhou, Guangdong, China
    Zhujiang Hospital of Southern Medical University
Aug 9, 2021

B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/70 T cells)

Recruiting
  • B Cell Malignancies
  • bi-4SCAR CD19/70 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 28, 2022

B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/22 T cells)

Recruiting
  • B Cell Malignancies
  • bi-4SCAR CD19/22 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 21, 2022

B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/79b T cells)

Recruiting
  • B Cell Malignancies
  • bi-4SCAR CD19/79b T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 28, 2022

B-cell Malignancies Trial in Guangzhou, Shenzhen, Kunming (4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20)

Unknown status
  • B-cell Malignancies
  • 4SCAR19 and 4SCAR22
  • +5 more
  • Guangzhou, Guangdong, China
  • +3 more
Sep 18, 2019

B Cell Lymphoma (BCL) Trial in Shenzhen (4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2)

Recruiting
  • B Cell Lymphoma (BCL)
  • 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2
  • Shenzhen, Guangdong, China
  • +2 more
Jun 10, 2020

Episiotomy; Complications, Scar Tissue Trial in Calgary (Episiotomy Scar Tissue Self-Scar Massage)

Not yet recruiting
  • Episiotomy; Complications
  • Scar Tissue
  • Episiotomy Scar Tissue Self-Scar Massage
  • Calgary, Alberta, Canada
    University of Calgary
Jun 8, 2023

B-cell Malignancies Trial in Shenzhen, Kunming (Therapeutic 4SCAR19 cells)

Unknown status
  • B-cell Malignancies
  • Therapeutic 4SCAR19 cells
  • Shenzhen, Guangdong, China
  • +1 more
Sep 18, 2019

CD19 Negative B-cell Malignancies Trial in Shenzhen, Shijiazhuang (Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20)

Recruiting
  • CD19 Negative B-cell Malignancies
  • Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20
  • Shenzhen, Guangdong, China
  • +2 more
Jun 10, 2020

T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,

Recruiting
  • T-cell Acute Lymphoblastic Leukemia
  • +3 more
  • Universal CD7-specific CAR gene-engineered T cells
  • Beijing, Beijing, China
  • +2 more
Aug 17, 2023

Autoimmune Diseases Trial in Shenzhen, Guilin (4SCAR T cells)

Recruiting
  • Autoimmune Diseases
  • 4SCAR T cells
  • Shenzhen, Guangdong, China
  • +1 more
Jul 17, 2022

Function and Scar in Trigger Finger Release

Recruiting
  • Trigger Finger
  • Trigger Finger Release through Transverse Incision
  • +2 more
  • Hamilton, Ontario, Canada
    St. Joseph's Healthcare
Jul 25, 2022

COVID-19 Trial (Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells), Placebo)

Not yet recruiting
  • COVID-19
  • Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
  • Placebo
  • (no location specified)
Sep 22, 2023

Moderna COVID-19 Bivalent Booster for Omicron BA.4/5

Recruiting
  • COVID-19
  • Moderna COVID-19 Vaccine
  • +3 more
  • Culver City, California
    Science37
Mar 9, 2023

COVID-19 on Clinical Outcomes and Management of IgG4 Related

Active, not recruiting
  • IgG4 Related Disease
  • Covid19
  • exposure to COVID19
  • Sha Tin, New Territories, Hong Kong
    Prince of Wales Hospital, The Chinese University of Hong Kong
Nov 18, 2022

Post COVID-19 Condition, Post-COVID-19 Syndrome, Post-COVID Syndrome Trial in Toronto (Monoplace Hyperbaric Chamber (Class III

Not yet recruiting
  • Post COVID-19 Condition
  • +5 more
  • Monoplace Hyperbaric Chamber (Class III medical device).
  • Toronto, Ontario, Canada
    Sunnybrook Health Sciences Centre
Oct 12, 2023

Long COVID Trial in Hong Kong (Chinese medicine nutritional supplement Cs4)

Recruiting
  • Long COVID
  • Chinese medicine nutritional supplement Cs4
  • Hong Kong, China
    The School of Chinese Medicine, HKU
Sep 26, 2023

Booster Dose of Comirnaty in Children Ages 6 Months Though 4

Not yet recruiting
  • SARS-CoV-2
  • COVID-19
  • COMIRNATY intramuscular injection
  • Tokyo, Japan
    Pfizer Local Country
Nov 8, 2023

Cancer Disease Trial in Shenzhen (bi-4SCAR PSMA/CD70 T cells)

Recruiting
  • Cancer Disease
  • bi-4SCAR PSMA/CD70 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

COVID-19 Trial in Calgary (Persuasive Appeal)

Completed
  • COVID-19
  • Persuasive Appeal
  • Calgary, Alberta, Canada
    Lucid Marketplace
Feb 8, 2023

Cancer Disease Trial in Shenzhen (bi-4SCAR GD2/CD70 T cells)

Recruiting
  • Cancer Disease
  • bi-4SCAR GD2/CD70 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Malignant Disease Trial in Shenzhen (bi-4SCAR GD2/CD56 T cells)

Recruiting
  • Malignant Disease
  • bi-4SCAR GD2/CD56 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

COVID-19 Trial in Brandenburg an der Havel (Palbociclib)

Withdrawn
  • COVID-19
  • Brandenburg an der Havel, Germany
    Universitätsklinikum Brandenburg an der Havel
Nov 3, 2022

COVID-19 Trial in Paris (Lymph node aspiration / Blood sampling)

Recruiting
  • COVID-19
  • Lymph node aspiration / Blood sampling
  • Paris, France
    GH Broca-Cochin-Hôtel-Dieu CIC 1417 Cochin-Pasteur
Jul 19, 2023